US Stock MarketDetailed Quotes

NUVL Nuvalent

Watchlist
  • 76.640
  • +0.900+1.19%
Close Mar 27 16:00 ET
4.91BMarket Cap-35317P/E (TTM)

About Nuvalent Company

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Company Profile

SymbolNUVL
Company NameNuvalent
Listing Date07/29/2021
Issue Price17.00
Founded2017
CEODr. James R. Porter, PhD
MarketNASDAQ
Employees92
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressOne Broadway,14th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-857-357-7000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Matthew Shair, PhD
  • Director and Scientific Founder
  • 360.39K
  • Dr. James R. Porter, PhD
  • Director, Chief Executive Officer and President
  • 5.21M
  • Alexandra Balcom, M.B.A.
  • Chief Financial Officer, Principal Accounting Officer and Treasurer
  • 2.02M
  • Dr. Christopher D. Turner, M.D.
  • Chief Medical Officer
  • 2.08M
  • Dr. Deborah Miller, J.D.,PhD
  • Chief Legal Officer and Secretary
  • 1.49M
  • Darlene Noci, A.C.I.S.
  • Chief Development Officer
  • --
  • Anna Protopapas
  • Independent Director
  • 553.69K
  • Dr. Sapna Srivastava, PhD
  • Independent Director
  • 171.95K
  • Dr. D. Gary Gilliland, M.D.,PhD
  • Independent Director
  • 174.18K
  • Dr. Andrew A. F. Hack, M.D.,PhD
  • Independent Director
  • 171.33K
  • Dr. Michael L. Meyers, M.D.,PhD
  • Independent Director
  • 366.82K
  • Dr. Cameron Wheeler, PhD
  • Independent Director
  • 181.72K
  • Dr. Joseph Pearlberg, M.D.,PhD
  • Independent Director
  • 168.39K
  • Dr. Emily Drabant Conley, PhD
  • Independent Director
  • 523.96K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg